Lilly Presents First Clinical Data for Investigational Ovarian Cancer Drug
Lilly presented clinical data for its investigational next-generation, folate receptor alpha-targeting antibody-drug conjugate in platinum-sensitive ovarian cancer.
Lilly presented clinical data for its investigational next-generation, folate receptor alpha-targeting antibody-drug conjugate in platinum-sensitive ovarian cancer.